Glucose and other reducing sugars react with an amino group and form complex compounds. CMA (Nω-carboxymethylarginine). This process, so called glycation, involves post-translational modification and possibly increases the risk of various diseases. In particular, the accumulation of advanced glycation end products (AGEs) in long lived tissues is reported that are increased not only by aging or diabetes, but by inflammation and oxidative stress.
We have carboxymethyl arginine (CMA), carboxymethyl lysine (CML), glycated bovine serum albumin standard, anti CML monoclonal antibody, anti-carboxyethyl lysine monoclonal antibody, etc.
CMA (Nω-carboxymethylarginine)
CMA is glyoxal derived acid-labile AGE for arginine residue. It was found in vitro-glycated collagen. CMA exists in vivo, and its serum level is elevated in deabetic patients.
[Odani et al, Biochem.Biophys.Res.Commun., 2001]
[Iijima et al, Biochem.J., 2000]
AGEs standard
CMA : Nω-(Carboxymethyl)-L-arginine (#CMA-1_02 for 2 mg / #CMA-1_05 for 5 mg)
CML : Nε-(Carboxymethyl)-L-lysine (#CML-1_05 for 5 mg / #CML-1_10 for 10 mg)
2.6 mol of CEL is generated in 1 mol of BSA by incubation with pyruvic acid.
HPLC purified this material is ready to use as standard in ELISA. Nε-(Carboxyethyl)-L-lysine (CEL) is thought to generate from the reaction between lysine residue and methylglyoxal (MG) in vivo proteins.
A part of lysine in BSA is carboxyethylated by pyruvic acid in this product.